- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07284784
Uno studio sul Buntanetap in partecipanti con PD
Uno Studio Clinico in Aperto che Indaga la Sicurezza a Lungo Termine di Buntanetap nel Trattamento di Partecipanti con Malattia di Parkinson
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Sarah MacCallum, BSN RN
- Numero di telefono: 484-875-3192
- Email: maccallum@annovisbio.com
Backup dei contatti dello studio
- Nome: Alexander Morin, PhD
- Email: morin@annovisbio.com
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- University of Alabama at Birmingham
-
Contatto:
- Candace Cromer
- Numero di telefono: 205-996-4034
- Email: candacecromer@uabmc.edu
-
Investigatore principale:
- Natividad Stover, M.D.
-
-
Arizona
-
Sun City, Arizona, Stati Uniti, 85351
- Reclutamento
- Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
-
Investigatore principale:
- Sara Dhanani, M.D.
-
Contatto:
- Serena Lowery
- Numero di telefono: 623-832-6500
- Email: serena.lowery@bannerhealth.com
-
-
California
-
Fountain Valley, California, Stati Uniti, 92708
- Reclutamento
- Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
-
Investigatore principale:
- Daniel Truong, M.D.
-
Contatto:
- Evan Moreno-Davis
- Numero di telefono: 714-378-5074
- Email: evan@pmdi.org
-
-
Colorado
-
Englewood, Colorado, Stati Uniti, 80113
- Reclutamento
- Cenexel Rocky Mountain Clinical Research
-
Contatto:
- Sally Modzelewski
- Numero di telefono: 720-776-0092
- Email: s.modzelewski@cenexel.com
-
Investigatore principale:
- Meagen Salinas, M.D.
-
-
Connecticut
-
Stamford, Connecticut, Stati Uniti, 06824
- Reclutamento
- New England Institute for Clinical Research (Ki Health Partners)
-
Contatto:
- Valerija Misev
- Numero di telefono: 125 203-914-1903
- Email: Valerija@neinh.com
-
Investigatore principale:
- Peter McAllister, M.D.
-
-
Florida
-
Aventura, Florida, Stati Uniti, 33180
- Reclutamento
- First Choice Neurology - Aventura Neurologic Associates
-
Investigatore principale:
- Jonathan Cross, M.D.
-
Contatto:
- Jonathan Palmquist
- Numero di telefono: 786-744-5596
- Email: jpalmquist@vintrials.com
-
Daytona Beach, Florida, Stati Uniti, 32117
- Reclutamento
- Arrow Clinical Trials
-
Contatto:
- Vinoothna Moluguri
- Numero di telefono: 386-316-6152
- Email: vmoluguri@arrowtrials.com
-
Investigatore principale:
- David Billmeier, M.D.
-
DeLand, Florida, Stati Uniti, 32720
- Reclutamento
- Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
-
Investigatore principale:
- Bruce Rankin, D.O.
-
Contatto:
- Erica Santoni
- Numero di telefono: 4608 1-386-785-2400
- Email: erica.santoni@accelclinical.com
-
Miami, Florida, Stati Uniti, 33172
- Reclutamento
- Professional Research Center
-
Contatto:
- Saylet Corbera
- Numero di telefono: 786-359-4091
- Email: RamirezMD@professionalresearchcenter.com
-
Miami, Florida, Stati Uniti, 33015
- Non ancora reclutamento
- Ezy Medical Research Co.
-
Contatto:
- Priscilla Hernandez
- Numero di telefono: 786-483-8162
- Email: phernandez@ezytrials.com
-
Ocala, Florida, Stati Uniti, 34470
- Reclutamento
- Renstar Medical Research
-
Investigatore principale:
- Annette Nieves, M.D.
-
Contatto:
- Sebastian Mesa
- Numero di telefono: 352-629-5800
- Email: sebastian.mesa@renstar.net
-
Tampa, Florida, Stati Uniti, 33613
- Reclutamento
- University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
-
Contatto:
- Erica Botting
- Numero di telefono: 813-974-8026
- Email: ericabotting@usf.edu
-
Investigatore principale:
- Robert Hauser, M.D., MBA
-
Winter Park, Florida, Stati Uniti, 32789
- Reclutamento
- Conquest Research
-
Contatto:
- Fabiola Perez
- Numero di telefono: 407-916-0060
- Email: fabiola.perez@conquestresearch.com
-
Investigatore principale:
- Rekha Gandhi, M.D.
-
-
Georgia
-
Decatur, Georgia, Stati Uniti, 30030
- Reclutamento
- iResearch Atlanta
-
Contatto:
- Elizabeth Davis
- Numero di telefono: 404-537-1281
- Email: e.davis@cenexel.com
-
Investigatore principale:
- Kimball Johnson, M.D.
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46256
- Reclutamento
- Josephson Wallack Munshower Neurology, P.C.
-
Investigatore principale:
- Kristi George, M.D.
-
Contatto:
- Tammy Root
- Numero di telefono: 1-317-573-6061
- Email: troot@jwmneuro.com
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
-
Contatto:
- Kelly Lyons
- Numero di telefono: 913-588-7159
- Email: klyons@kumc.edu
-
Investigatore principale:
- Rajesh Pahwa, M.D.
-
-
Michigan
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Reclutamento
- Quest Research Institute
-
Investigatore principale:
- Aaron Ellenbogen, D.O.
-
Contatto:
- Savannah Carra
- Numero di telefono: 248-957-8940
- Email: savannah.carra@questri.com
-
-
New York
-
New York, New York, Stati Uniti, 10019
- Reclutamento
- Mount Sinai Hospital
-
Investigatore principale:
- Joohi Jimenez-Shahed, M.D.
-
Contatto:
- Sofya Glazman
- Numero di telefono: 646-493-1862
- Email: sofya.glazman@mountsinai.org
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke Department of Neurosurgery
-
Investigatore principale:
- Kyle Mitchell, M.D.
-
Contatto:
- Vera George
- Numero di telefono: 919-668-3885
- Email: vera.george@duke.edu
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University Wexner Medical Center
-
Investigatore principale:
- Zachary Jordan, M.D.
-
Contatto:
- Victoria Miller
- Numero di telefono: 614-688-8672
- Email: victoria.miller@osumc.edu
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti, 74136
- Reclutamento
- The Movement Disorder Clinic of Oklahoma
-
Contatto:
- Elise Gibson
- Numero di telefono: 918-392-4530
- Email: mdcclinicaltrials@gmail.com
-
Investigatore principale:
- Kevin Klos, M.D.
-
-
Pennsylvania
-
Willow Grove, Pennsylvania, Stati Uniti, 19090
- Reclutamento
- Abington Neurology
-
Investigatore principale:
- David Weisman, M.D.
-
Contatto:
- Brian Weingartner
- Numero di telefono: 130 215-957-9250
- Email: brian.weingartner.ana@gmail.com
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29401
- Reclutamento
- Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
-
Contatto:
- Sandra Wilson
- Numero di telefono: 843-792-3223
- Email: wilsosan@musc.edu
-
Investigatore principale:
- Vanessa Hinson, M.D., PhD
-
-
Tennessee
-
Cordova, Tennessee, Stati Uniti, 38018
- Reclutamento
- Neurology Clinic, P.C.
-
Contatto:
- Ye Liu
- Numero di telefono: 901-747-1111
- Email: yliu@neuroclinic.org
-
Investigatore principale:
- Kendrick Henderson, M.D.
-
Memphis, Tennessee, Stati Uniti, 38157
- Reclutamento
- Veracity Neuroscience LLC
-
Contatto:
- Hannah Touliatos
- Numero di telefono: 901-604-0345
- Email: hannah@veracityneuroscience.com
-
Investigatore principale:
- Mark LeDoux, M.D., PhD
-
-
Texas
-
Round Rock, Texas, Stati Uniti, 78681
- Reclutamento
- Central Texas Neurology
-
Contatto:
- Koni Lopez
- Numero di telefono: 512-218-1222
- Email: k.lopez@ctncpa.org
-
Investigatore principale:
- Elizabeth Peckham, M.D.
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- Reclutamento
- University of Virginia Health System (UVAHS) - Adult Neurology Clinic
-
Investigatore principale:
- Binit Shah, M.D.
-
Contatto:
- Lauren Miller
- Numero di telefono: 434-982-6599
- Email: fdk5dn@uvahealth.org
-
-
Washington
-
Spokane, Washington, Stati Uniti, 99202
- Reclutamento
- Inland Northwest Research
-
Investigatore principale:
- Jason Aldred, M.D.
-
Contatto:
- Aaron Dahl
- Numero di telefono: 509-960-2818
- Email: adahl@inwresearch.com
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Medical College of Wisconsin
-
Contatto:
- Shelby Schold
- Numero di telefono: 414-955-0698
- Email: sschold@mcw.edu
-
Investigatore principale:
- Karen Blindauer, M.D.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and
a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.
b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.
i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.
-
Have a support person who will accompany the participant on study visits at designated times.
-
Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
-
Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
-
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
-
Intrauterine device (IUD),
-
Intrauterine hormone-releasing system (IUS),
-
Bilateral tubal occlusion,
-
Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),
-
Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
- Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54
-
-
Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
- Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
- IUD,
- IUS,
- Bilateral tubal occlusion.
-
No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.
-
Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
- Standard of care anti-parkinsonian medication,
- Cholinesterase inhibitors and/or memantine medication,
- Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
- Mood-stabilizing psychotropic agents including, but not limited to, lithium,
-
Adequate visual and hearing ability (physical ability to perform all the study assessments).
-
Good general health with no disease expected to interfere with the study.
Exclusion Criteria:
-
Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).
-
A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.
-
Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.
Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54
-
Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.
-
Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).
-
Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.
-
Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
-
Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
-
Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.
-
Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
-
A learning disability or developmental delay.
-
Participants whom the site PI deems to be otherwise ineligible.
-
A known allergy to the investigational drug or any of its components.
Inactive ingredients of the investigational medicinal product:
- Silicified microcrystalline cellulose
- Dibasic calcium phosphate dihydrate
- Mannitol
- Stearic acid
- Hypromellose (capsule shells structure)
- Titanium dioxide (opacifier of the capsule shells)
-
Is currently pregnant, breast-feeding, and/or lactating.
-
Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Cohort 1 - buntanetap
Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun |
buntanetap capsules 30 mg by mouth daily |
|
Sperimentale: Cohort 2 - buntanetap
Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. |
buntanetap capsules 30 mg by mouth daily |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety of buntanetap
Lasso di tempo: 36-months of treatment
|
Safety assessments of participants with PD receiving treatment with buntanetap |
36-months of treatment
|
|
Adverse Events (AE)
Lasso di tempo: 36-months of treatment
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention |
36-months of treatment
|
|
Treatment Emergent Adverse Events (TEAE)
Lasso di tempo: 36-months of treatment
|
TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state |
36-months of treatment
|
|
Serious Adverse Events (SAE)
Lasso di tempo: 36-months of treatment
|
SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly |
36-months of treatment
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Laurie Sanders, Ph.D., Duke Clinical Research Institute
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ANVS-25002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .